APTOSE BIOSCIENCES Inc. joined the Beat AML collaboration, developed by The Leukemia & Lymphoma Society and the Knight Cancer Institute at Oregon Health & Science University.
Aptose’s lead investigational anticancer therapeutic APTO-253 will be profiled extensively against primary cells from hundreds of AML patient samples collected by Beat AML contributors.
Under the agreement, Aptose and the Knight Cancer Institute will collaborate on research related to APTO-253, which is designed to provide further insights into the optimal genetic profile of patients likely to benefit from APTO-253 therapy.
APTO-253 is a small molecule that acts through induction of the innate tumor suppressor gene Krüppel-like factor 4 and expression of the downstream cell cycle regulator p21.
THE CLEVELAND CLINIC will use IBM Watson technology to accelerate the use of genomic-based medicine.
The Lerner Research Institute’s Genomic Medicine Institute at Cleveland Clinic plans to evaluate Watson’s ability to help oncologists develop more personalized care to patients for a variety of cancers. The goal is to use Watson to correlate data from genome sequencing to medical journals, studies and clinical records, identifying patterns in genome sequencing and medical data.
The pilot initiative is an extension of Cleveland Clinic programs focused on big data in healthcare. Given the depth and speed of Watson’s ability to review massive databases, the objective of the collaboration is to increase the number of patients who have access to care options tailored to their disease’s DNA.
MD ANDERSON CANCER CENTER and Summit Medical Group signed a letter of intent to develop a joint, outpatient cancer center, as an extension of MD Anderson’s partnership with Cooper University Health Care, that will provide an integrated, multidisciplinary approach to oncology care in northern New Jersey.
Summit Medical Group will become a member of MD Anderson Cancer Network. The agreement is the first of its kind between MD Anderson and a physician-owned and governed multispecialty group. MD Anderson will provide clinical oversight and management for the program, which will include radiation oncology, medical oncology, infusion and diagnostic imaging.
